Evidence map›Paper›PMID 40936197›Full record

ArticlemAbs2025

Rational design of antibodies with pH-dependent antigen-binding properties using structural insights from broadly neutralizing antibodies against α-neurotoxins.

Jack Wade, Nina Štrancar, Monica L Fernández-Quintero, Suzana Siebenhaar, Tom Jansen, Edward P W Meier, Timothy P Jenkins, Sara P Bjørn, Giang T T Nguyen, Bruno Lomonte and 15 more

Abstract read
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Computational design of pH-sensitive binders.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Jack WadeDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0001-5465-7399
Nina ŠtrancarDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0009-0003-3902-0084
Monica L Fernández-QuinteroCenter for Molecular Biosciences Innsbruck, Department of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-6811-6283
Suzana SiebenhaarDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0009-0005-3307-8423
Tom JansenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0001-8006-8627
Edward P W MeierDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0002-0287-6693
Timothy P JenkinsDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0003-2979-5663
Sara P BjørnDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0003-3341-6160
Giang T T NguyenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0002-3536-9903
Bruno LomonteInstituto Clodomiro Picado, Facultad de Microbiologia, Universidad de Costa Rica, San Jose, Costa Rica.ORCID 0000-0003-2419-6469
José Maria GutiérrezInstituto Clodomiro Picado, Facultad de Microbiologia, Universidad de Costa Rica, San Jose, Costa Rica.ORCID 0000-0001-8385-3081
Christoffer V SørensenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0001-7727-936X
Johannes R LoefflerCenter for Molecular Biosciences Innsbruck, Department of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-5724-655X
Arijit PaulDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0001-9293-7519
Tulika TulikaDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0001-7345-8037
Johnny ArnsdorfDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0002-2738-0811
Sanne SchoffelenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0003-2664-8561
Emil V S LundquistDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0009-0008-4634-4665
Jennifer SørensenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0009-0003-2271-3466
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, San Diego, CA, USA.ORCID 0000-0001-7153-3769
Bjørn G VoldborgDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0002-7005-1642
Markus-Frederik BohnDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0002-0369-1922
Esperanza Rivera-de-TorreDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0002-0272-6150
J Preben MorthDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0003-4077-0192
Andreas H LaustsenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Denmark.ORCID 0000-0001-6918-5574

Funding

HORIZON EUROPE European Research Council 850974Novo Nordisk Foundation NNF20SA0066621Novo Nordisk Foundation NNF24OC0088714Villum Fonden 00025302Wellcome TrustWellcome Trust 221702/Z/20/Z
6 · The paper itself

Abstract

Antibodies that bind in a pH-dependent manner to their antigens show promise for enhanced neutralization potency and blocking capacity against extracellular targets. However, because the mechanisms governing pH-dependent antigen binding remain poorly understood, engineering approaches are often limited to incorporating histidine residues in the antibody complementarity-determining regions. Here, we use a panel of human monoclonal antibodies with neutralizing activity to long-chain α-neurotoxins (LNTxs) to investigate pH-dependent antigen binding. The antibodies vary in their light chains but have conserved histidine residues in their variable domains, allowing us to explore how other residues may affect pH dependence. Comparative structural and molecular dynamics studies between two antibodies with and without pH-dependent antigen-binding properties reveal that both antibodies neutralize LNTxs by mimicking LNTx-receptor interactions through their heavy chains. We hypothesize that part of the pH-dependency can be controlled by the light chain through modulation of water access to residues at the heavy-light-chain interface. We show that pH-dependent antigen-binding properties can be introduced into monoclonal antibodies through the substitution of selected residues at the heavy-light-chain interface. Specifically, we replaced tyrosine residues in the light chain with small polar and apolar amino acid residues in a structurally related anti-LNTx antibody with limited inherent pH-dependent antigen-binding properties, and found that these smaller substitutions enhanced pH-dependence more effectively than histidine substitutions alone. Our findings suggest a strategy for engineering pH-dependent antigen binding in antibodies that goes beyond the exclusive use of histidine doping.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingNeurotoxinsComplementarity Determining RegionsHumansHydrogen-Ion ConcentrationMolecular Dynamics SimulationProtein EngineeringAntibodies, MonoclonalAntibodies, NeutralizingComplementarity Determining RegionsNeurotoxinsacid-switched antibodiesmonoclonal antibodiesphage displaypH-dependent antigen bindingsnakebitesnake venom

Identifiers

PMID40936197
PMCPMC12439581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.